Skip to content
Clinical Trials – home
The NetherlandsBack to the Netherlands

Clinical trials in Nieuwegein – page 14

2 029 clinical trials in Nieuwegein, The Netherlands across 2 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Nieuwegein at a glance
2 029
clinical trials
  • Research sites2
Type of trial
Recruitment status
Quick filters

2 029 trials in Nieuwegein

Open in trial search

Venetoclax added to fludarabine, cytarabine and gemtuzumab ozogamicin (drug combination) in children with relapsed acute myeloid leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years
  • Substances:Azacitidine
  • Sponsor:Prinses Maxima Centrum voor Kinderoncologie B.V.

Discontinuation of methotrexate (drug combination) in rheumatoid arthritis patients using TNF inhibitors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Adalimumab
  • Sponsor:Sint Maartenskliniek

Phase 1/2 Study of VS-7375 with Drug Combination in Patients with Advanced KRAS G12D‑Mutated Solid Tumors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Verastem Inc.

Rituximab and venetoclax treatment for 6 vs 26 cycles in patients with relapsed or refractory chronic lymphocytic leukemia

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Venetoclax
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Safety and Efficacy of TSRA-196 (rnaivt9315 and rnacs24757) in Adults with Lung or Liver Disease due to Alpha‑1 Antitrypsin Deficiency

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:RNACS24757
  • Sponsor:Tessera Therapeutics Inc.

Vitiligo

Recruiting

Phase IIb Randomized, Double‑Blind Study of GIA632 in Adults with Nonsegmental Vitiligo

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:GIA632
  • Sponsor:Novartis Pharma AG

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of DNL952 in Adults with Late‑Onset Pompe Disease

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:DNL952
  • Sponsor:Denali Therapeutics Inc.

Evaluation of NXT007 versus Emicizumab Prophylaxis in Patients with Hemophilia A

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Emicizumab
  • Sponsor:F. Hoffmann-La Roche AG

A Phase III study of NXT007 compared with simoctocog alfa prophylaxis in patients with Hemophilia A without inhibitors

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:RO7589655
  • Sponsor:F. Hoffmann-La Roche AG

Study of Fludeoxyglucose (18F) PET Imaging of Brain Metabolism in Patients with Persistent Post‑COVID Syndrome

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · Healthy volunteers
  • Substances:Fludeoxyglucose (18F)
  • Sponsor:Amsterdam UMC Stichting

Myelofibrosis+1

Recruiting

Study of pelabresib (DAK539) plus ruxolitinib versus placebo plus ruxolitinib in adult patients with myelofibrosis who are JAK‑inhibitor‑naive

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ruxolitinib
  • Sponsor:Novartis Pharma AG

Safety and Antitumor Activity of PF-08634404 Alone or with Enfortumab Vedotin in Adults with Locally Advanced or Metastatic Urothelial Cancer

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Enfortumab Vedotin
  • Sponsor:Pfizer Inc.

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Nieuwegein

What the registry says about research in the country

01 Respiratory Medicine

Innovative research focusing on idiopathic pulmonary fibrosis and related conditions, evaluating new therapeutic approaches for lung diseases. Studies include assessment of novel treatments for systemic autoimmune rheumatic diseases with lung involvement.

  • Pulmonary Fibrosis Treatment
  • Interstitial Lung Disease
  • Rheumatic Disease-Related Lung Conditions

Multiple trials are investigating both targeted therapies and comprehensive treatment approaches.

02 Oncology Research

Comprehensive studies in cancer treatment, particularly focusing on prostate cancer and urothelial cancer. Advanced imaging techniques and novel therapeutic combinations are being evaluated for improved patient outcomes.

  • Advanced Colorectal Cancer
  • Acute Myeloid Leukemia
  • Bladder Cancer Therapeutics

Trials are exploring personalized treatment approaches and innovative drug combinations.

03 Neurological Disorders

Research initiatives addressing status epilepticus and post-cardiac arrest care. Studies include innovative approaches for treating dementia and related behavioral issues.

  • Post-Cardiac Arrest Care
  • Dementia Management
  • Stroke Prevention

Investigations focus on both acute neurological conditions and long-term management strategies.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.